CRUSE MICHAEL (Senior VP, Corporate Operation) purchased 121.0% of their position (7.50K shares) of ONKURE THERAPEUTICS, INC. on the open market
Open‑market purchase worth $25.4K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 9/2/2022ACC: 0001209191-22-048534
Officer· Senior VP, Corporate Operation
Since Apr 2021
+7.50K
Net shares
Net buyer
$25.4K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
7.50K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+7.50K
Price / share
$3.39
Trade value
$25.45K
% of position
121.0%
9/1/2022
6.20K→13.70K
Total
Net shares
+7.50K
Net value
$25.45K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 9/1/2022 | P · Purchase | +7.50K | $3.39 | $25.45K | 121.0% | 6.20K | 13.70K |
| Total | +7.50K | $25.45K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned31.76K
Total
31.76K direct31.76K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 31.76K | Direct |
| Total | 31.76K | 31.76K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported